Research on Breast Cancer Treatment

• Enobosarm: A multicenter, open-label, randomized, parallel, phase II study demonstrated that for the treatment of ER+ advanced breast cancer with oral Sarm enobosarm, the clinical benefit rate in the 9mg group was 25.0% at 24 weeks, and that in the 18mg group was 26.6%. The incidence of serious adverse reactions was 8.3% and 15.6% respectively. Currently, a phase III study on enobosarm is ongoing, aiming to evaluate the efficacy and safety of its single-agent treatment for AR+/ER+/HER2- metastatic breast cancer.
• EG017: The domestic oral Sarm EG017 is a prodrug of enobosarm. The related phase I study is in progress. It is planned to recruit 81 patients with AR+/ER+/HER2- advanced breast cancer to assess its safety, maximum tolerated dose, etc. The existing data indicates that its overall safety is favorable.

Other Related Research

• Combination Therapy Research: A phase II clinical study explored the efficacy and safety of enobosarm combined with pembrolizumab in the treatment of AR+ TNBC. With a median follow-up of 24.9 months, the clinical benefit rate was 25.0%, the median progression-free survival was 2.6 months, and the median overall survival rate was 25.5%. Another phase III study is investigating the safety and efficacy of enobosarm combined with a cyclin-dependent kinase inhibitor in the treatment of AR+/ER+/HER2- and AR% ≥ 40% metastatic breast cancer.
• Research on Risks and Side Effects: Studies have pointed out that Sarm products have numerous risks and side effects. For example, after two men took lgd-4033 for 9 weeks and rad-140 for only 4 weeks, they developed hepatocellular cholestatic injury, also had a detrimental effect on high-density lipoprotein cholesterol, and caused moderate damage to the hypothalamic-pituitary-testicular axis, resulting in temporary testosterone suppression.